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OBJECTIVES The purpose of this study was to determine whether a common variant (PIA2) of the
membrane glycoprotein (GP) IIIa gene is associated with myocardial infarction (MI) or
coronary artery disease (CAD).
BACKGROUND Platelet GP IIb/IIIa is believed to play a central role in MI, binding fibrinogen, cross-linking
platelets and initiating thrombus formation. Genetically determined differences in binding
properties of GP IIb/IIIa might result in changes in platelet activation or aggregation and
affect the risk of MI or CAD.
METHODS To determine associations (odds ratios [OR] $1.5 to 2.0) of genotype with MI or CAD,
blood was drawn from 791 patients (pt) undergoing angiography. A 266 base pair fragment
of the GP IIIa gene was amplified by the polymerase chain reaction and digested with the
MspI restriction enzyme. Genotypes were identified after electrophoresis of digestion
products in 1.5% agarose gel.
RESULTS Of the 791 pt, 225 had acute (n 5 143) or previous MI, and 276 did not have MI or unstable
angina. The PIA2 allele was carried by 33.8% of MI pt versus 26.9% of no-MI control
subjects, OR 5 1.39 (95% CI, 0.95 to 2.04, p 5 0.09). Angiographically, 549 pt had severe
(.60% coronary stenosis) CAD, and 170 had normal coronary arteries (,10% stenosis). The
PIA2 allele was found in 31.0% of CAD pt versus 28.2% of no-CAD control subjects, OR 5
1.14 (CI, 0.78 to 1.67, p 5 0.50). When adjusted for six standard risk factors, ORs were 1.47
(CI, 0.98 to 2.20, p 5 0.062) for MI and 1.20 (CI, 0.80 to 1.81, p 5 0.38) for CAD.
CONCLUSIONS The PIA2 variant of the gene encoding GP IIIa is modestly associated (OR ' 1.5) with
nonfatal MI but shows little if any association with CAD per se. (J Am Coll Cardiol 1999;
33:727–33) © 1999 by the American College of Cardiology
Platelet adhesion and aggregation play a central role in
physiologic and pathologic thrombus formation. The plate-
let membrane receptor glycoprotein (GP) IIb/IIIa is central
to these processes at a molecular level, binding von Wille-
brand factor, which is responsible for platelet adhesion to
abnormal endothelium, and fibrinogen, a bivalent protein
cross-linking platelets and causing platelet aggregation (1–
3). Platelet aggregation is particularly active at sites of
eroded or ruptured coronary atherosclerotic plaques that
underlie unstable angina and myocardial infarction (MI)
and of endothelial disruption associated with coronary
angioplasty (4–6). The importance of GP IIb/IIIa receptors
in platelet aggregation and thrombus formation in these
clinical syndromes is also attested to by the therapeutic
benefit demonstrated for selective GP IIb/IIIa receptor
inhibitors in clinical trials (7–14). In addition, ex vivo
platelet reactivity has been linked to outcome in patients
after MI (6).
The two major platelet membrane glycoproteins, GP IIb
and GP IIIa, are highly polymorphic. In some instances,
these polymorphisms have been shown to predispose to
alloantigenicity or autoantigenicity or form the basis for
alloimmune thrombocytopenia (15,16). Contemporary ge-
netic techniques have defined the basis for these polymor-
phisms, which are most often point mutations in the
encoding genes (16,17).
One of the most frequently implicated polymorphisms in
syndromes of immune-mediated platelet destruction is an
alloantigen referred to as PIA (or Zw) (18,19). Serologic
studies demonstrated PIA to reside in the platelet glyco-
protein IIIa (20). Newman and colleagues have identified
the molecular basis (16): the more common allele, PIA1, was
found to have a leucine at amino acid position 33 of the
mature glycoprotein IIIa, whereas the less common poly-
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morphism PIA2 had a proline at this position. The change in
amino acids was shown to be the result of a substitution of
cytosine for thymidine at nucleotide position 1565, located
in exon 2 of the glycoprotein IIIa gene (16).
Given the central role of platelets in vascular thrombosis,
interest has grown in the possibility that mutations in
platelet receptor glycoproteins, possibly including common
polymorphisms such as PIA1/A2, may represent independent
risk factors for vascular thrombosis. Weiss and colleagues
found an unexpectedly high frequency of PIA2 homozygos-
ity in families with a high prevalence of early coronary
events (21). Subsequently, they reported the same poly-
morphism to be a risk factor for unstable angina and MI in
a general population, based on a case–control study (22).
However, this finding could not be confirmed in a subse-
quent report from the Physicians Health Study (23). Nei-
ther study was angiographically controlled. To shed further
light on an association of the PIA1/A2 polymorphism of GP
IIIa with coronary heart disease, we studied a relatively large
patient population whose coronary status was defined an-
giographically. The study was performed in compliance
with the hospital’s human studies committee and with
subjects’ written informed consent.
METHODS
Study hypotheses. We tested whether carriage of the GP
IIIa PIA2 allele is associated with an increased risk for: 1)
MI, and 2) coronary artery disease (CAD) in patients
studied by coronary angiography.
Patient and control populations. Study patients and con-
trol subjects consisted of consecutive, stable, consenting
subjects presenting for coronary angiography at LDS Hos-
pital either because of symptoms relating to suspected CAD
or because of unrelated conditions requiring angiographic
evaluation (e.g., valvular disease, cardiomyopathy). Subjects
were of unrestricted age and gender who gave written
informed consent for a blood draw for deoxyribonucleic acid
(DNA) extraction at the time of angiography, to be used in
studies approved by the hospital’s institutional review board.
An independent, free-living, volunteer population sample,
without clinically evident disease, served as a further control
group. Subjects were residents of Utah, southwestern Idaho
or southeastern Wyoming, a population that is ethnically
primarily of Northern European (Anglo-Scandinavian) de-
scent that previously has been shown to be genetically
representative of North American Caucasians (24).
Key demographic characteristics of subjects were re-
corded on computerized angiographic data forms, including
age, gender and history of MI (25). Assessment of CAD
was made by review of angiograms by the patient’s cardiol-
ogist, who was uninformed as to GP IIIa genotype. Results
were entered into the computer database in a format
modified after the Coronary Artery Surgery Study protocol
(25,26).
Patients were designated to have significant CAD if they
had .60% stenosis of at least one coronary artery or major
branch (n 5 549) and no CAD if ,10% stenosis was
present (n 5 170). Of CAD patients, 129 were hospitalized
with an acute MI (203 had an MI at some time), 205 with
unstable angina, 165 with other chest pain syndromes, 84
with valvular heart disease and 1 with cardiomyopathy,
singly or in combination. Of the control subjects with
normal coronary arteries, 107 presented with chest pain
syndromes without CAD or MI, 47 with valvular heart
disease and 6 with cardiomyopathy, singly or in combina-
tion, and the rest for other reasons. Patients with minor
CAD (10% to 60% stenosis; n 5 72) were designated as
having “indeterminate” CAD status and were not included
in CAD analyses.
The MI group consisted of 225 patients, 143 with acute
(same hospitalization) MI, the rest with previous MI only.
A history of MI was identified and entered on the cath-lab
report form by the attending physician: old MI was defined
on the basis of a current electrocardiogram (ECG) and
historical data; recent MI (i.e., MI occurring during the
index hospitalization) was, in addition, to be associated with
positive cardiac serum markers. The no-MI control group
(n 5 276) was selected from other patients undergoing
angiography, excluding those with a history of MI at any
time as well as those with CAD associated with either
unstable angina or other chest pain syndromes. Of no-MI
control subjects, 146 presented with chest pain without
severe CAD, 76 with valvular disease and 9 with cardiomy-
opathy, alone or in combination, and the rest for other
reasons.
Designations of MI and CAD status were made by the
attending physician without knowledge of DNA genotype
after considering angiographic results together with patient
history and ECG.
Deoxyribonucleic acid extraction. Approximately 20 to
30 ml of blood was withdrawn by venipuncture at the
time of coronary angiography and collected in ethylenedi-
aminetetraacetic acid (EDTA). The leukocyte buffy coat
was separated by centrifugation. Recovered leukocytes
were washed in TNE buffer (10 mmol/L Tris base, 10
mmol/L NaCl, 1 mmol/L EDTA) and resuspended in 2
ml of a solution of sodium chloride (75 mmol/L) and
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 95% confidence interval
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiogram
EDTA 5 ethylenediaminetetraacetic acid
GP 5 glycoprotein
MI 5 myocardial infarction
OR 5 odds ratio
PCR 5 polymerase chain reaction
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EDTA (25 mmol/L) to which 50 ml proteinase K (10
mg/ml) and 100 ml of 20% sodium dodecyl sulfate were
added. The solution was incubated at 65°C overnight.
After incubation, the mixture was combined with 0.5
volumes equilibrated phenol and 0.5 volumes chloroform:
isoamyl alcohol (24:1) and placed on a shaker for 1 h
followed by centrifugation at 1,000 g for 10 min. The
upper phase was removed and reextracted with one
volume chloroform and centrifuged. The upper phase was
collected and mixed with 0.1 volume 3 mol/L sodium
acetate (pH 5.2), shaken, and combined with 2 volumes
cold isopropanol. Precipitated DNA was removed with a
glass hook and resuspended in TE (0.1 mol/L Tris, 0.001
mol/L EDTA, pH 8.0).
Deoxyribonucleic acid genotyping. To identify the PIA
genotypes, the following primers were used: 59 TTC TGA
TTG CTG GAC TTC TCT T 39 and 59 TCT CTC CCC
ATG GCA AAG AGT 39.
The polymerase chain reaction (PCR) amplification pro-
tocol consisted of an initial denaturation segment of 94°C
for 5 min. After this, each cycle consisted of three segments
(94°C for 60 s, 57°C for 45 s and 72°C for 60 s). This cycle
was repeated 35 times followed by an additional extension
cycle at 72°C for 15 min. The 266 base pair fragment
amplified by PCR was digested with MspI. Polymorphic
genotypes were identified after electrophoresis of digestion
products in 1.5% agarose gel and staining with 1 mg/ml
ethidium bromide. The gels were read blinded to clinical
and angiographic results by a single experienced reader. A
representative gel is shown in Figure 1.
Statistical planning and analysis. Power calculations in-
dicated that to determine odds ratios (ORs) for CAD or MI
of the PIA2 polymorphic allele carriage in the GP IIIa gene
of between 1.5 and 2.0 with a power of 80% at a two-sided
alpha level of 0.05 in a population with a carriage rate of the
PIA2 allele of 25% would require samples of between 151
and 464 subjects per group (GB Stat for Windows).
Accordingly, we assembled and studied a population of 791
subjects; 69% of the population samples had severe CAD,
and 28% had a history of MI.
Allelic and genotypic frequencies were determined from
observed genotype counts, and the expectations of the
Hardy–Weinberg equilibrium were evaluated by chi-square
analysis. Comparisons between allelic and genotypic fre-
quencies used chi-square analysis. Associations were as-
sessed as ORs; 95% confidence intervals (CIs) were calcu-
lated as previously described (27). Exploratory analyses were
prospectively planned in subgroups of interest. Univariate
and multivariate logistic regression, used to determine crude
and adjusted ORs for associations with the genetic marker,
respectively, were done using SPSS 6.1 (Chicago, IL).
Multivariate analyses used a backward, conditional ap-
proach, entering simultaneously genotype and six major
CAD risk factors: age, gender, cholesterol concentration,
smoking status, diabetic status and history of hypertension
(see Table 3 for details).
RESULTS
Characteristics of the patient groups. A total of 791
angiographic subjects were studied. Their age averaged 64
years (range 17 to 89); 225 had a history of MI, and 549 had
severe CAD. Key patient characteristics are summarized by
disease subgroup in Table 1. The control and diseased
groups differed in that those with CAD were older, and
more frequently male, smokers and (trend) diabetic. Those
with MI were more frequently male and smokers, and more
likely (trend) to have a history of hypertension (although
post-MI, treated systolic blood pressure was slightly lower).
Genotypic and allelic frequencies in the control groups.
Genotypic and allelic frequencies for the study groups are
shown in Table 2. The PIA2 allelic frequency was 15.0% in
the no-MI angiographic control group (n 5 276), 15.9% in
the no-CAD control group (n 5 170) and 12.8% in the
smaller group (n 5 94) of normal volunteers. Genotypic
distributions in the control groups conformed with Hardy–
Weinberg expectations. The homozygotic PIA2/A2 genotype
appeared in 3.3% and 3.5% of the no-MI and no-CAD
control groups and PIA2 allele carriage (homo- or heterozy-
gous) in 26.9% and 28.2%, respectively.
Association between the PIA2 polymorphism and MI.
Among patients with a diagnosis of MI (n 5 225), the PIA2
polymorphic allelic frequency was 17.8% (OR 5 1.22, CI
0.87 to 1.71, p 5 0.24 vs. no-MI control subjects) (Table 2).
The heterozygous or homozygous carriage rate of the PIA2
allele of 33.8% was associated with an OR for MI in the
entire angiographic cohort of 1.39 (CI 0.95 to 2.04, p 5
0.09). Simultaneously adjusting the OR for the presence of
Figure 1. Example of GP IIIa PIA1/A2 polymorphic genotyping
using polyacrylamide gel electrophoresis of PCR amplification
products.
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six standard risk factors gave an adjusted OR of 1.47 (CI
0.97 to 2.22, p 5 0.062) (Table 3). Other independent
associates, in order of strength of association, included:
gender, smoker, genotype, hypertension and age (Table 3).
Using the smaller normal volunteer group as control gave a
crude OR 5 1.67 (CI 0.96 to 2.90, p 5 0.07).
Association between the PIA2 polymorphism and CAD.
Among patients with severe CAD (n 5 549), the PIA2 allelic
frequency was 15.9% (OR 5 1.06, CI 0.76 to 1.48, p 5 0.73
vs. no-CAD control subjects) (Table 2). Carriage of the PIA2
allele occurred in 31.0% and was associated with an OR for
CAD of 1.14 (CI 0.78 to 1.67, p 5 0.50). Adjustment of the
OR for the standard risk factors did not significantly improve
the association of PIA2 carriage with CAD (OR 5 1.20, CI
0.80 to 1.81, p 5 0.38). Indeed, genotype was not selected as
a multivariate associate of CAD; these included, in order of
strength of association, gender, age, smoking and diabetes.
Using the smaller normal volunteer group as control gave a
crude OR 5 1.47 (CI 0.88 to 2.45, p 5 0.14).
Table 1. Characteristics of Diseased and Control Patients
Characteristic Patients Control Subjects
MI
Number 225 276
Age (yr) (mean 6 SD) 63 6 11 62 6 11
Range 31 to 89 17 to 89
Gender (% male) 79 57*
Hypertension (%) 51 44
Systolic BP (mm Hg) 132 6 22 138 6 23†
Diastolic BP (mm Hg) 71 6 10 72 6 11
Smoker (%) 36 20*
Diabetes (%) 14 11
Cholesterol (mg/dl) 205 6 41 206 6 53
(n) (174) (170)
Hypercholesterolemia
(% $220 mg/dl)
31 36
CAD
Number 549 170
Age (yr) (mean 6 SD) 65 6 11 61 6 12*
Range 36 to 89 17 to 84
Gender (% male) 80 50*
Hypertension (%) 49 42
Systolic BP (mm Hg) 138 6 24 138 6 23
Diastolic BP (mm Hg) 72 6 10 73 6 12
Smoker (%) 27 18‡
Diabetes (%) 16 11
Cholesterol (mg/dl) 206 6 45 204 6 56
(n) (417) (102)
Hypercholesterolemia
(% $220 mg/dl)
34 32
*p , 0.001, †p , 0.01, ‡p , 0.05 control subjects versus patients.
BP 5 blood pressure; CAD 5 coronary artery disease; MI 5 myocardial infarction.
Table 2. Genotypic Distributions and Allelic Frequencies of PIA1/A2 Polymorphism Among Patients and Control Subjects
Group
PIA1/A1,
n (%)
PIA1/A2,
n (%)
PIA2/A2,
n (%)
%PIA1
Allele
%PIA2
Allele
MI/controls
MI (n 5 225) 149 (66.2) 72 (32.0) 4 (1.8) 82.2 17.8
No MI (n 5 276) 202 (73.2) 65 (23.6) 9 (3.3) 85.0 15.0
CAD/controls
CAD (n 5 549) 379 (69.0) 157 (28.6) 13 (2.4) 83.3 16.7
No CAD (n 5 170) 122 (71.8) 42 (24.7) 6 (3.5) 84.1 15.9
Free-living normals
(n 5 94)
72 (76.6) 20 (21.3) 2 (2.1) 87.2 12.8
Abbreviations as in Table 1.
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Homozygotic carriage of PIA2 was infrequent and not
significantly predictive of either MI or CAD.
Association between the PIA1/A2 polymorphism and MI
in prespecified subgroups. The PIA1/A2 polymorphism
might affect risk primarily in a certain patient subgroup
(e.g., in younger patients) (22). We performed stratified
analyses of associations of PIA2 carriage in the subgroups
defined by presence or absence of age $60 years, male
gender, smoking, diabetes, hypertension or cholesterol
$220 mg/dl. A proposed increase in disease association in
younger (,60 years) MI patients (21,22) could not be
confirmed: OR 5 0.90, CI 0.48 to 1.70, age ,60 years (n 5
182); OR 5 1.80, CI 1.11 to 2.93, age $60 years (n 5 319).
Analyses in other stratified subgroups did not point to
notable heterogeneities.
DISCUSSION
Summary of study results. In a moderately large, angio-
graphically defined population, we found a modest associ-
ation between carriage of the variant GP IIIa allele, PIA2,
and nonfatal MI (OR ' 1.5, p 5 0.06, adjusted for six other
baseline risk factors). Comparison with the smaller normal
volunteer population lent further support to an association
of the polymorphism with MI. However, an association
between allele carriage and CAD per se was not established
(OR ' 1.2, with an OR of .1.8 excluded with 95%
confidence). Overall, the results support the hypothesis that
the PIA2 polymorphic allele may facilitate coronary throm-
bosis and hence MI through an alteration in platelet
reactivity. Stratified analyses of the MI association revealed
a notable heterogeneity only for age, with a stronger
association in elderly than younger MI survivors.
Comparison with recent literature reports. Previous stud-
ies have reported divergent results for the association be-
tween coronary events and the PIA1/A2 polymorphism
(21–23). In an initial report, Weiss et al. found an unex-
pectedly high frequency of homozygosity for PIA2 among
family members in kindreds with a high prevalence of
coronary events at a younger age (,60 years) (21). Weiss
and coworkers subsequently conducted a case–control study
of 71 patients with MI or unstable angina and 68 inpatient
control subjects matched for age, race and gender (22). They
found the prevalence of PIA2 to be 2.1 times greater among
case patients than control subjects (39% vs. 19%, p 5 0.01).
In patients with onset of disease before age 60 years,
polymorphic allelic frequency was 3.6 times greater than in
age-matched control subjects (50% vs. 13.9%, p 5 0.002).
Odds ratios for a coronary event were 2.8 (CI 1.2 to 6.4) for
all patients and 6.2 (CI 1.8 to 22.4) for those ,60 years of
age, suggesting a strong association between the PIA1/A2
polymorphism and acute coronary thrombosis, especially for
events occurring before the age of 60 years.
More recently, Ridker et al. evaluated the predictive value
of the PIA1/A2 polymorphism for MI, stroke and venous
thrombosis among 704 patients with events and 704
matched subjects remaining free of thrombotic events dur-
ing a prospective follow-up averaging 8.6 years in men
participating in the Physician’s Health Study (23). The
frequency of the PIA2 allele was found to be similar to the
control frequency (14.8%) among men who had MI (13.5%,
p 5 0.4), stroke (13.4%, p 5 0.5) or venous thrombosis
(14.5%, p 5 0.9). Carriage rates of the PIA2 allele were
26.4% and 25.2% in control subjects and MI patients,
respectively. The relative risk associated with carriage of
PIA2 was 0.96 (CI 0.8 to 1.2) for any vascular events and
0.93 (CI 0.7 to 1.2) for MI, neither a significant difference.
Similarly, there was no evidence for an association with the
polymorphism in subgroups analyzed by age, smoking
status, family history of disease, hypercholesterolemia, hy-
Table 3. Multivariate Logistic Regression Models for CAD and MI
Variable B SE Wald df Significance r
Exp (B)
(OR)
Predictive Model for MI
Gender 5 M 1.04 0.21 23.49 1 , 0.001 0.177 2.81
Smoker 5 Y 0.72 0.22 10.95 1 , 0.001 0.114 2.06
Hypertension 5 Y 0.36 0.19 3.53 1 0.060 0.047 1.43
Genotype* 0.39 0.21 3.48 1 0.062 0.046 1.47
Age (yr) 0.016 0.009 3.35 1 0.067 0.044 1.016
Constant 22.40 0.62 14.94 1 , 0.0001 — —
Predictive Model for CAD
Gender 5 M 1.59 0.20 60.42 1 , 0.0001 0.273 4.89
Age (yr) 0.050 0.009 30.98 1 , 0.0001 0.192 1.051
Smoker 5 Y 0.57 0.24 5.74 1 0.017 0.069 1.77
Diabetes 5 Y 0.71 0.30 5.72 1 0.017 0.069 2.02
Constant 23.26 0.63 26.85 1 , 0.0001 — —
*Containing PIA2 allele. Modeling used Backward Conditional Logistic Regression (SPSS 6.1 for Power Macintosh), initially entering age (in years), and dichotomous status
(yes/no) for diabetes; hypertension; gender 5 male, and PIA2/A2 homozygosity. Cholesterol level (in mg/dl), available in 560, also was entered in a preliminary analysis, but was
not selected as an independent multivariate predictor.
M 5 male; OR 5 odds ratio; Y 5 yes. Other abbreviations as in Table 1.
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pertension or diabetes. Aspirin use had no effect on the
findings.
Our study went beyond these two in defining CAD
angiographically. Overall, the findings are intermediate
between the negative result of the large, prospective Physi-
cian’s Health Study (23) and the positive result of the
smaller, earlier study of Weiss et al. (22); in our population,
an association of modest degree (OR ' 1.5) was found for
MI but not for CAD per se, when adjusted for baseline
variables or when using the normal volunteer group as
control subjects.
Explanation for differences among studies and analysis of
results. There may be several explanations for differences in
results among the three studies. Differences may be due to
chance. The study of Weiss et al. was substantially smaller
than the other two and had wider confidence intervals (22).
Thus, chance is more likely to have played a role in that
result. Indeed, control carriage rates for the PIA2 allele were
lower in the Weiss study (19%) than in ours or the Ridker
study, which were similar ('26% to 28%).
Results of the studies may also differ because of differ-
ences in the selection of control patients. Allelic frequencies
may differ among populations of different ethnic, genetic or
gender background. Weiss selected control subjects from a
population of patients admitted to the hospital for nonisch-
emic disorders (22); Ridker selected control subjects from a
cohort of healthy male physicians with a low frequency of
coronary risk factors (23); we selected subjects coming to
angiography for suspected cardiac disease (e.g., undefined
chest pain, valvular disease or cardiomyopathy) but shown
to be free of MI or CAD, as well as a smaller free-living
sample. Finally, differences may arise because of differences
in study design (prospective [23] vs. retrospective [22]) or in
the way coronary events were defined (MI, [unstable]
angina, angiographic CAD, coronary interventions, death
or various combinations).
The extent to which chance, selection biases and study
design contributed to differences in results among these
studies is uncertain. Additional observations from larger
samples testing prospective subgroup (and overall) hypoth-
eses will be needed to resolve these issues. However, if the
results of the three studies to date are combined in an
informal meta-analysis, an OR for MI of '1.2 is found for
carriers of PIA2 (p 5 NS). However, additional studies
would be welcome, especially those with prospective
follow-up in populations with a greater prevalence of
potentially interacting risk factors than was present in the
Physician’s Health Study.
Pathophysiologic considerations. The stronger associa-
tion of PIA2 carriage with MI than CAD is consistent with
the hypothesis that the polymorphism affects primarily
thrombotic (platelet-dependent) rather than other mecha-
nisms of ischemic heart disease pathogenesis. However, the
association with MI observed was modest.
Why is the effect of the PIA1/A2 polymorphism of a
critical platelet receptor protein (GP IIIa) on MI risk
difficult to ascertain when a wealth of experimental and
clinical evidence is consistent with a central role for platelets
(2–14)? One explanation is that the polymorphism is
unassociated with significant differences in the function of
the GP IIb/IIIa fibrinogen receptor. Another possibility is
that the PIA2 allele is in linkage disequilibrium with a
disease-associated locus on some but not all PIA2-bearing
haplotypes. (Although the polymorphism clearly has been
implicated in immune-mediated platelet dysfunction syn-
dromes [15,16], its functional role in non–immune-
mediated processes, if any, has not been defined.) Another
possibility is that the polymorphism acts within a polygen-
etically (rather than monogenetically) determined model.
Indeed, there is much evidence to suggest that the patho-
genesis of ischemic heart disease is complex and polygenetic
in origin in the vast majority of patients, with important
environmental factors interacting with multiple, interacting
and counteracting genetic determinants, many with low
penetrance. Consistent with current understanding of
pathophysiology, we did find the risk of the GP IIIa
polymorphism to be more clearly associated with transi-
tional events to MI, which include coronary thrombosis,
than CAD per se. Thus, further research on platelet-
associated genetic factors is warranted, particularly for MI.
Study strengths and limitations. This study has the ad-
vantage of being of relatively large size and angiographically
controlled. The possibility exists of inadvertent genetic
selection bias appearing in “normal” subjects that are se-
lected for coronary angiography. Comparisons with the
free-living population sample in our study puts this possi-
bility into perspective. Also, our PIA2 allelic carriage rates
for the volunteer and angiographic control samples (23%,
28%) are similar to (straddle) the carriage rate of controls in
the Physician’s Health Study (26%). Finally, we performed
conditional logistic regression to adjust for differences in
baseline factors (resulting in only minor changes in the
associated ORs).
Mistyping is a theoretical concern and was dealt with by
retyping '10% of our samples, with identical results. Our
study was “retrospective” with respect to MI events, raising
the possibility of changes in prevalence of PIA2 among cases
and control subjects due to differential survival rates after
MI based on PIA2 carrier status. A similar concern applies to
the study of Weiss et al. (22), but they found a greater
relative risk for the PIA2 allele in younger coronary event
survivors, unlike our results or those of the Physician’s
Health Study. The Physician’s Health Study determined
relative risk associations during prospective follow-up.
However, our sample may have an advantage over that of
Ridker et al. (23) in being drawn from a population with a
greater prevalence of coronary risk factors, more typical of
the overall United States population than the unusually low
risk sample recruited into the Physician’s Health Study; low
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penetrant genetic variants may require the presence of
interacting environmental factors to achieve expression.
Conclusions. In an angiographically defined North Amer-
ican population of European extraction, we found a modest
association (OR ' 1.5, p 5 0.06) between a relatively
common variant (PIA2) of the gene encoding GP IIIa and
nonfatal MI but not CAD per se. This supports the
hypothesis that the polymorphism may facilitate coronary
thrombosis through effects on platelet reactivity. These
angiographically defined results address inconsistencies be-
tween two earlier studies (22,23). Because the pathogenetic
mechanisms of ischemic heart disease are complex and
multifactorial, with environmental factors interacting with
multiple genetic determinants that have low penetrance,
further research on platelet-associated genetic factors is
warranted.
Reprint requests and correspondence: Dr. Jeffrey L. Anderson,
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